Loading...

We've got a brand new version of Simply Wall St! Try it out

Pacific Biosciences of California

Nasdaq:PACB
Snowflake Description

Mediocre balance sheet with limited growth.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
PACB
Nasdaq
$710M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The last earnings update was 12 days ago. More info.


Add to Portfolio Compare Print
  • Pacific Biosciences of California has significant price volatility in the past 3 months.
PACB Share Price and Events
7 Day Returns
0.9%
NasdaqGS:PACB
4.8%
US Life Sciences
0.7%
US Market
1 Year Returns
-37.8%
NasdaqGS:PACB
18.7%
US Life Sciences
13.7%
US Market
PACB Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Pacific Biosciences of California (PACB) 0.9% -15% -19.9% -37.8% -41.6% -33.8%
US Life Sciences 4.8% 6.7% 5.4% 18.7% 93.2% 117.8%
US Market 0.7% 4.7% 6.1% 13.7% 39.2% 44.5%
1 Year Return vs Industry and Market
  • PACB underperformed the Life Sciences industry which returned 18.7% over the past year.
  • PACB underperformed the Market in United States of America which returned 13.7% over the past year.
Price Volatility
PACB
Industry
5yr Volatility vs Market

Value

 Is Pacific Biosciences of California undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Pacific Biosciences of California. This is due to cash flow or dividend data being unavailable. The share price is $4.64.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Pacific Biosciences of California's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Pacific Biosciences of California's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGS:PACB PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-09-30) in USD $-0.76
NasdaqGS:PACB Share Price ** NasdaqGS (2019-11-18) in USD $4.64
United States of America Life Sciences Industry PE Ratio Median Figure of 18 Publicly-Listed Life Sciences Companies 33.43x
United States of America Market PE Ratio Median Figure of 2,924 Publicly-Listed Companies 18.25x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Pacific Biosciences of California.

NasdaqGS:PACB PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:PACB Share Price ÷ EPS (both in USD)

= 4.64 ÷ -0.76

-6.13x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Pacific Biosciences of California is loss making, we can't compare its value to the US Life Sciences industry average.
  • Pacific Biosciences of California is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Pacific Biosciences of California's expected growth come at a high price?
Raw Data
NasdaqGS:PACB PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -6.13x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts
16.5%per year
United States of America Life Sciences Industry PEG Ratio Median Figure of 15 Publicly-Listed Life Sciences Companies 2.74x
United States of America Market PEG Ratio Median Figure of 2,038 Publicly-Listed Companies 1.46x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Pacific Biosciences of California, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Pacific Biosciences of California's assets?
Raw Data
NasdaqGS:PACB PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-09-30) in USD $0.33
NasdaqGS:PACB Share Price * NasdaqGS (2019-11-18) in USD $4.64
United States of America Life Sciences Industry PB Ratio Median Figure of 36 Publicly-Listed Life Sciences Companies 5.07x
United States of America Market PB Ratio Median Figure of 5,086 Publicly-Listed Companies 1.76x
NasdaqGS:PACB PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:PACB Share Price ÷ Book Value per Share (both in USD)

= 4.64 ÷ 0.33

13.92x

* Primary Listing of Pacific Biosciences of California.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Pacific Biosciences of California is overvalued based on assets compared to the US Life Sciences industry average.
X
Value checks
We assess Pacific Biosciences of California's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Life Sciences industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Life Sciences industry average (and greater than 0)? (1 check)
  5. Pacific Biosciences of California has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Pacific Biosciences of California expected to perform in the next 1 to 3 years based on estimates from 4 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
16.5%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Pacific Biosciences of California expected to grow at an attractive rate?
  • Unable to compare Pacific Biosciences of California's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Pacific Biosciences of California's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.
  • Pacific Biosciences of California's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqGS:PACB Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGS:PACB Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts 16.5%
NasdaqGS:PACB Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 4 Analysts 25.9%
United States of America Life Sciences Industry Earnings Growth Rate Market Cap Weighted Average 17.3%
United States of America Life Sciences Industry Revenue Growth Rate Market Cap Weighted Average 7.6%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 14.4%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGS:PACB Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGS:PACB Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2022-12-31 176 -74 1
2021-12-31 168 -71 2
2020-12-31 125 -97 -87 4
2019-12-31 88 -77 -109 3
2019-11-19
NasdaqGS:PACB Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-09-30 82 -79 -115
2019-06-30 79 -76 -111
2019-03-31 76 -73 -109
2018-12-31 79 -66 -103
2018-09-30 84 -68 -93
2018-06-30 89 -71 -90
2018-03-31 88 -70 -93
2017-12-31 93 -68 -92
2017-09-30 94 -60 -90
2017-06-30 96 -58 -86
2017-03-31 97 -64 -79
2016-12-31 91 -68 -74

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Pacific Biosciences of California is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Pacific Biosciences of California's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGS:PACB Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below

All data from Pacific Biosciences of California Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGS:PACB Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2022-12-31 -0.48 -0.48 -0.48 1.00
2021-12-31 -0.45 -0.32 -0.58 2.00
2020-12-31 -0.52 -0.39 -0.64 4.00
2019-12-31 -0.71 -0.69 -0.72 3.00
2019-11-19
NasdaqGS:PACB Past Financials Data
Date (Data in USD Millions) EPS *
2019-09-30 -0.76
2019-06-30 -0.75
2019-03-31 -0.77
2018-12-31 -0.76
2018-09-30 -0.73
2018-06-30 -0.73
2018-03-31 -0.82
2017-12-31 -0.87
2017-09-30 -0.91
2017-06-30 -0.92
2017-03-31 -0.86
2016-12-31 -0.83

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Pacific Biosciences of California will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Pacific Biosciences of California's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Pacific Biosciences of California has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Pacific Biosciences of California performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Pacific Biosciences of California's growth in the last year to its industry (Life Sciences).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Pacific Biosciences of California does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Pacific Biosciences of California's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Pacific Biosciences of California's 1-year growth to the US Life Sciences industry average as it is not currently profitable.
Earnings and Revenue History
Pacific Biosciences of California's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Pacific Biosciences of California Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGS:PACB Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-09-30 82.49 -114.84 61.52 61.62
2019-06-30 78.73 -110.76 58.46 61.01
2019-03-31 75.69 -108.71 57.92 61.77
2018-12-31 78.63 -102.56 58.79 62.59
2018-09-30 84.04 -92.53 57.78 61.96
2018-06-30 89.42 -89.50 58.23 63.45
2018-03-31 87.92 -92.50 58.79 64.66
2017-12-31 93.47 -92.19 59.12 65.32
2017-09-30 94.26 -90.46 57.72 65.95
2017-06-30 95.83 -85.93 55.66 67.59
2017-03-31 96.50 -78.89 51.34 68.23
2016-12-31 90.71 -74.38 47.79 67.62
2016-09-30 101.27 -56.75 47.57 66.11
2016-06-30 90.07 -37.44 46.49 64.80
2016-03-31 94.26 -30.88 46.12 62.32
2015-12-31 92.78 -31.70 45.19 60.44
2015-09-30 73.41 -49.26 42.41 58.02
2015-06-30 80.11 -60.25 41.48 53.55
2015-03-31 66.60 -67.45 39.65 50.94
2014-12-31 60.59 -66.16 38.03 48.23
2014-09-30 52.82 -64.42 37.09 47.03
2014-06-30 39.62 -75.74 37.96 45.76
2014-03-31 34.25 -77.08 38.34 45.01
2013-12-31 28.18 -79.29 38.75 45.22
2013-09-30 24.93 -83.73 42.75 43.34
2013-06-30 20.28 -85.97 42.14 45.54
2013-03-31 21.52 -87.99 44.32 45.13
2012-12-31 25.98 -94.47 47.66 47.62

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Pacific Biosciences of California has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Pacific Biosciences of California has efficiently used its assets last year compared to the US Life Sciences industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Pacific Biosciences of California improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Pacific Biosciences of California's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Life Sciences industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Pacific Biosciences of California has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Pacific Biosciences of California's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Pacific Biosciences of California's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Pacific Biosciences of California is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Pacific Biosciences of California's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Pacific Biosciences of California's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 4.9x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Pacific Biosciences of California Company Filings, last reported 1 month ago.

NasdaqGS:PACB Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-09-30 51.01 15.55 49.20
2019-06-30 75.75 15.23 66.84
2019-03-31 94.85 14.94 82.87
2018-12-31 114.06 14.66 102.35
2018-09-30 131.88 14.38 115.75
2018-06-30 85.47 14.12 63.49
2018-03-31 102.74 13.87 79.26
2017-12-31 86.10 13.64 62.87
2017-09-30 101.41 13.36 83.97
2017-06-30 115.86 13.08 102.60
2017-03-31 69.19 16.43 56.05
2016-12-31 84.67 16.11 71.98
2016-09-30 98.68 15.79 87.33
2016-06-30 108.07 15.50 102.47
2016-03-31 88.78 15.22 91.53
2015-12-31 73.54 14.95 82.27
2015-09-30 41.37 14.81 58.91
2015-06-30 33.84 14.57 72.67
2015-03-31 40.47 14.34 79.15
2014-12-31 54.95 13.99 101.35
2014-09-30 53.04 13.91 99.31
2014-06-30 59.02 13.71 105.03
2014-03-31 75.53 13.53 118.74
2013-12-31 69.18 13.35 112.53
2013-09-30 83.54 13.17 126.94
2013-06-30 100.40 13.01 106.97
2013-03-31 107.09 12.85 112.31
2012-12-31 109.38 0.00 100.58
  • Pacific Biosciences of California's level of debt (30.5%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (21.3% vs 30.5% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Pacific Biosciences of California has less than a year of cash runway based on current free cash flow.
  • Pacific Biosciences of California has less than a year of cash runway if free cash flow continues to grow at historical rates of 3.7% each year.
X
Financial health checks
We assess Pacific Biosciences of California's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Pacific Biosciences of California has a total score of 3/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Pacific Biosciences of California's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Pacific Biosciences of California dividends.
If you bought $2,000 of Pacific Biosciences of California shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Pacific Biosciences of California's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Pacific Biosciences of California's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGS:PACB Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
United States of America Life Sciences Industry Average Dividend Yield Market Cap Weighted Average of 8 Stocks 0.4%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 1956 Stocks 2.3%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.4%
United States of America Top 25% Dividend Yield 75th Percentile 3.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGS:PACB Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2022-12-31
2021-12-31
2020-12-31
2019-12-31
2019-11-19

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Pacific Biosciences of California has not reported any payouts.
  • Unable to verify if Pacific Biosciences of California's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Pacific Biosciences of California's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Pacific Biosciences of California has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Pacific Biosciences of California's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Pacific Biosciences of California afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Pacific Biosciences of California has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Pacific Biosciences of California's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Mike Hunkapiller
COMPENSATION $1,610,866
AGE 70
TENURE AS CEO 7.8 years
CEO Bio

Dr. Michael W. Hunkapiller, also known as Mike, Ph.D., has been the Chief Executive Officer and President of Pacific Biosciences of California, Inc. since January 2012 and since January 1, 2012 respectively. Dr. Hunkapiller is a General Partner of Alloy Ventures Inc. since November 2004. He joined Alloy Ventures in 2004 and focuses on life sciences companies making use of information technology, in particular those looking to optimize clinical and research processes. He has spent 21 years at Applied Biosystems. He joined in 1983 and has held several scientific and business positions before being promoted in 1992 to Executive Vice President. From 1995 to 2004, Dr. Hunkapiller held the company's top offices as General Manager and President. His tenure saw the invention of tools for modern molecular biology in which innovations such as the polymerase chain reaction and automation of tedious manual processes led to an increase in genomic and proteomic data. Throughout this period, Dr. Hunkapiller was pivotal in crafting the research and development strategies and alliances that elevated ABI to the foremost supplier of molecular-biology reagents and instrumentation in academic and industrial laboratories. He was a Founder of ABI's sister company Celera Genomics (CRA) and Senior Vice President of Applera Corporation. Prior to joining ABI, Dr. Hunkapiller was a Senior Research Fellow in the Division of Biology at the California Institute of Technology. He was previously employed at Aclara Biosciences Inc and Perkin-Elmer Corp. Dr. Hunkapiller has been an Executive Chairman of Pacific Biosciences of California, Inc. since October 27, 2011 and has been its Director since 2005. He has been a Director at Codon Devices Inc. since June 1, 2005. He served as a Director at Fluidigm Corporation. He has been Director of RainDance Technologies, Inc. since July 2007. He serves as a Director of NuGEN Technologies, Inc. He held a Board seat at Verinata Health. Dr. Hunkapiller has authored more than 100 scientific publications, is an inventor on more than two- dozen patents and has served on several editorial boards of scientific journals. He has received several awards for his contributions to life science research, including the development of the automated DNA sequencing systems used to sequence the human genome. Dr. Hunkapiller was elected in 2008 to the National Academy of Engineering for his life-long dedication to the human genome mapping project and the field of comparative genetics. He received a Ph.D. in Chemical Biology from Caltech in 1974 and a B.S. in Chemistry from Oklahoma Baptist University in 1970.

CEO Compensation
  • Mike's compensation has increased whilst company is loss making.
  • Mike's remuneration is lower than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Pacific Biosciences of California management team in years:

9.8
Average Tenure
66.5
Average Age
  • The average tenure for the Pacific Biosciences of California management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Mike Hunkapiller

TITLE
Executive Chairman
COMPENSATION
$2M
AGE
70
TENURE
7.8 yrs

Susan Barnes

TITLE
Executive VP & CFO
COMPENSATION
$1M
AGE
65
TENURE
9.8 yrs

James Phillips

TITLE
Senior Vice President of Research & Development
COMPENSATION
$617K
AGE
68
TENURE
9.8 yrs

Stephen Turner

TITLE
Co-Founder & CTO
COMPENSATION
$467K
AGE
51
TENURE
19.3 yrs

Jonas Korlach

TITLE
Chief Scientific Officer
TENURE
7.3 yrs

Trevin Rard

TITLE
Head of Investor Relations

Stephen Moore

TITLE
VP, General Counsel & Corporate Secretary

Ben Gong

TITLE
VP of Finance & Treasurer
Board of Directors Tenure

Average tenure and age of the Pacific Biosciences of California board of directors in years:

8.1
Average Tenure
69
Average Age
  • The tenure for the Pacific Biosciences of California board of directors is about average.
Board of Directors

Mike Hunkapiller

TITLE
Executive Chairman
COMPENSATION
$2M
AGE
70
TENURE
8.1 yrs

Bill Ericson

TITLE
Lead Independent Director
COMPENSATION
$106K
AGE
60
TENURE
9.8 yrs

Randy Livingston

TITLE
Independent Director
COMPENSATION
$96K
AGE
65
TENURE
10.8 yrs

DF Shapiro

TITLE
Independent Director
COMPENSATION
$87K
AGE
78
TENURE
7.2 yrs

Kathy Ordoñez

TITLE
Director
COMPENSATION
$686K
AGE
68
TENURE
4.9 yrs

Joe Bonventre

TITLE
Member of the Scientific Advisory Board
AGE
69

Harold Craighead

TITLE
Member of the Scientific Advisory Board

Roger Kornberg

TITLE
Member of the Scientific Advisory Board
AGE
72

Watt Webb

TITLE
Member of the Scientific Advisory Board

Kenneth Johnson

TITLE
Member of the Scientific Advisory Board
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
29. Aug 19 Sell Magnetar Capital, LLC Company 02. Jul 19 27. Aug 19 -509,020 $6.08 $-2,792,945
29. Aug 19 Buy Magnetar Capital, LLC Company 02. Jul 19 19. Aug 19 171,299 $6.14 $1,031,423
30. Apr 19 Sell Magnetar Capital, LLC Company 21. Mar 19 29. Apr 19 -840,883 $7.38 $-6,146,987
30. Apr 19 Buy Magnetar Capital, LLC Company 05. Mar 19 05. Mar 19 8,864 $7.38 $65,410
21. Feb 19 Sell James Phillips Individual 19. Feb 19 19. Feb 19 -7,231 $7.17 $-51,817
21. Feb 19 Sell Kathy Ordoñez Individual 19. Feb 19 19. Feb 19 -6,933 $7.17 $-49,696
21. Feb 19 Sell Susan Barnes Individual 19. Feb 19 19. Feb 19 -11,987 $7.16 $-85,851
21. Feb 19 Sell Michael Hunkapiller Individual 19. Feb 19 19. Feb 19 -13,335 $7.19 $-95,825
X
Management checks
We assess Pacific Biosciences of California's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Pacific Biosciences of California has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

What Investors Should Know About Pacific Biosciences of California Inc's (NASDAQ:PACB) Financial Strength

While small-cap stocks, such as Pacific Biosciences of California Inc (NASDAQ:PACB) with its market cap of US$596m, are popular for their explosive growth, investors should also be aware of their balance sheet to judge whether the company can survive a downturn.

Simply Wall St -

What You Must Know About Pacific Biosciences of California Inc's (NASDAQ:PACB) Market Risks

Every stock in the market is exposed to this volatility, which is linked to the fact that stocks prices are correlated in an efficient market. … Beta can be a useful tool to understand how much a stock is influenced by market risk (volatility). … Any stock with a beta of greater than one is considered more volatile than the market, while those with a beta below one are either less volatile or poorly correlated with the market.

Simply Wall St -

Who Are Pacific Biosciences of California Inc's (NASDAQ:PACB) Major Shareholders?

Today, I will be analyzing Pacific Biosciences of California Inc’s (NASDAQ:PACB) recent ownership structure, an important but not-so-popular subject among individual investors. … The impact of a company's ownership structure affects both its short- and long-term performance. … Although this is an important factor for long-term investors, many investors can also be impacted by institutional presence and their high-volume trading.

Simply Wall St -

Have Investors Priced In Healthcare Growth For Pacific Biosciences of California Inc (NASDAQ:PACB)?

is a healthcare company operating in an industry,. … Life sciences companies, in particular, are operating in a difficult environment prompted by a more challenging healthcare agenda … The global need for innovative, cost-effective medicines continues to rise, whilst regulators and healthcare providers require more transparency and proven effectiveness

Simply Wall St -

What does Pacific Biosciences of California Inc's (NASDAQ:PACB) Balance Sheet Tell Us About Its Future?

While small-cap stocks, such as Pacific Biosciences of California Inc (NASDAQ:PACB) with its market cap of US$476.07m, are popular for their explosive growth, investors should also be aware of their balance sheet to judge whether the company can survive a downturn. … Companies operating in the Life Sciences industry,

Simply Wall St -

Does Pacific Biosciences of California Inc's (NASDAQ:PACB) -59.38% Earnings Decline Reflect A Long-Term Trend?

When Pacific Biosciences of California Inc's (NASDAQ:PACB) announced its latest earnings (30 September 2017), I wanted to understand how these figures stacked up against its past performance. … The two benchmarks I used were Pacific Biosciences of California's average earnings over the past couple of years, and its industry performance. … Each year, for the past five years Pacific Biosciences of California's top-line has risen by 27.24% on average, indicating that the company is in a high-growth period with expenses shooting ahead of revenues, leading to annual losses.

Simply Wall St -

How Financially Strong Is Pacific Biosciences of California Inc (PACB)?

Looking at PACB’s most recent $33.8M liabilities, the company has been able to meet these obligations given the level of current assets of $109.0M, with a current ratio of 3.23x. … NasdaqGS:PACB Historical Debt Dec 7th 17 Does PACB face the risk of succumbing to its debt-load? … Investors' risk associated with debt is very low with PACB, and the company has plenty of headroom and ability to raise debt should it need to in the future.Next Steps: Are you a shareholder?

Simply Wall St -

Company Info

Description

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company’s single molecule real-time (SMRT) sequencing technology enables single molecule real-time detection of biological processes. It offers PacBio RS II and Sequel Systems that conducts, monitors, and analyzes single molecule biochemical reactions in real time. The company also provides consumable products, including SMRT cells, as well as various reagent kits, such as template preparation, binding, and sequencing kits. Its customers include research institutions; commercial laboratories; genome centers; clinical, government, and academic institutions; genomics service providers; pharmaceutical companies; and agricultural companies. The company markets its products through a direct sales force in North America and Europe, as well as primarily through distribution partners in Asia, the Middle East, Africa, and Latin America. The company was formerly known as Nanofluidics, Inc. Pacific Biosciences of California, Inc. was founded in 2000 and is headquartered in Menlo Park, California.

Details
Name: Pacific Biosciences of California, Inc.
PACB
Exchange: NasdaqGS
Founded: 2000
$710,076,516
153,033,732
Website: http://www.pacb.com
Address: Pacific Biosciences of California, Inc.
1305 O’Brien Drive,
Menlo Park,
California, 94025,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS PACB Common Stock Nasdaq Global Select US USD 27. Oct 2010
DB P09 Common Stock Deutsche Boerse AG DE EUR 27. Oct 2010
Number of employees
Current staff
Staff numbers
401
Pacific Biosciences of California employees.
Industry
Life Sciences Tools and Services
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/11/19 00:24
End of day share price update: 2019/11/18 00:00
Last estimates confirmation: 2019/11/10
Last earnings filing: 2019/11/07
Last earnings reported: 2019/09/30
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.